OAS Comment letters
THIS PAGE IS HIDDEN - USE THE ONE LATER DOWN THE MENU FOR UPDATES
2024
- WIll be updated shortly.
2023
- September 1, 2023 - OAS Comment Letter on Reporting Nuclear Medicine Injection Extravasations as Medical Events as described in Docket ID NRC-2022-0218
- April 4, 2023 - OAS Comment Letter on Interim state agreement (SA) procedure, SA-802, Standing Committee for Reviewing Emerging Medical Technologies (STC-22-059)
- February 3, 2023 - OAS Comment Letter on , Interim Procedure SA-300, Reporting Material Events, and the Interim Handbook on Nuclear Material Event Reporting for the Agreement States (STC-22-033) and the Revised Interim Handbook on Nuclear Material Event Reporting for the Agreement States (STC-22-065)
2022
- December 1, 2022 - OAS Comment Letter on the Preliminary regulatory basis for the 10 CFR Part 35 rulemaking to establish requirements for rubidium-82 generators and emerging medical technologies (RCPD-22-010)
- October 22, 2022 - OAS Letter to recommend potential license conditions to the Nuclear Regulatory Commission (NRC) for review and concurrence prior to the upcoming regulatory changes for Category 3 quantities of radioactive materials
- June 17, 2022 - OAS Comment Letter on draft Commission paper: “Rulemaking Plan on Release of Animals Receiving
Treatment Containing Byproduct Material.” (RCPD-22-002) - February 11, 2022 - OAS Comment Letter on Multi-Agency Radiation Survey and Site Investigation Manual (MARSSIM), Revision 2 (Docket ID No. EPA-HQ-OAR-2021-0276)
- January 31, 2022 - OAS Comment Letter on Draft licensing guidance for the “Superficial Manual Brachytherapy CivaDermTM Device” (RCPD-21-015)
2021
- December 21, 2021 - OAS Comment Letter on the Regulatory Basis for the Decommissioning Financial Assurance for Sealed and Unsealed Radioactive Materials (RCPD-21-008
- December 21, 2021 - OAS Comment Letter on Draft Commission Paper: “Petition for Rulemaking and Rulemaking Plan on Reporting Nuclear Medicine Injection Extravasations as Medical Events” (RCPD-21-012)
- November 19, 2021 - OAS Comment Letter on draft licensing guidance for Alpha Tau’s Alpha DaRT TM (Diffusing Alphaemitters Radiation Therapy) - 10 CFR 35.1000, “Other medical uses of byproduct material or radiation from byproduct material.” (RCPD-21-009)
- November 1, 2021 - OAS Comment Letter on Draft Regulatory Guide 8.39, Release of Patients Administered Radioactive Materials, Revision 2 (RG 8.39) (RCPD-21-007).
- October 6, 2021 - OAS Comment Letter on the Inspection Procedures associated with Inspection Manual Chapter (IMC) 2800 “Materials Inspection Program” (RCPD-21-006)
- July 1, 2021 - OAS Comment Letter on “Notice of Interpretation on Industrial Radiographic Operations at Temporary Radiography Jobsites and an Agreement State Compatibility Category Change; Request for Comments” (STC-21-032) - specifically interpretation of 10 CFR 34.41
- January 15, 2021 - OAS Comment Letter on the Revised State Agreement Procedure (SA), Periodic Meetings Between IMPEP Reviews (STC-20-077)
|
|